Journal of Advanced Research · 10 authors, 2 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This preclinical study evaluated niclosamide-loaded nanoparticles (Ncl-NPs) in a mouse model of bleomycin-induced pulmonary fibrosis. The study found that Ncl-NPs attenuated and reversed established fibrosis by inhibiting fibroblast activation and epithelial-mesenchymal transition, primarily through modulating M2 macrophages and blocking TGF-β/Smad and Stat3 signaling pathways.
The study used a bleomycin-induced mouse model of pulmonary fibrosis and in vitro cell experiments to investigate the effects of niclosamide-loaded nanoparticles (Ncl-NPs). Researchers administered Ncl-NPs via tail vein injection to mice after bleomycin injury. Central results showed that Ncl-NPs significantly reduced hydroxyproline content, fibrosis score, and collagen expression, with a 2.5 mg/kg dose performing comparably to or better than 5 mg/kg of free niclosamide. Ncl-NPs were also demonstrated to reverse established fibrosis. Mechanistically, Ncl-NPs were found to inhibit fibroblast activation and epithelial-mesenchymal transition by modulating M2 macrophages and blocking the TGF-β/Smad and Stat3 signaling pathways. The findings suggest Ncl-NPs as a potential strategy to improve the delivery and efficacy of niclosamide for treating pulmonary fibrosis.
